Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents

Rationale Metabotropic glutamate receptors and muscarinic M 4 receptors have been proposed as novel targets for various brain disorders, including schizophrenia. Both receptors are coupled to G o/i proteins and are expressed in brain circuits that are important in schizophrenia. Therefore, their mut...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology 2018-10, Vol.235 (10), p.2897-2913
Main Authors: Cieślik, Paulina, Woźniak, Monika, Rook, Jerri M., Tantawy, Mohammed N., Conn, P. Jeffrey, Acher, Francine, Tokarski, Krzysztof, Kusek, Magdalena, Pilc, Andrzej, Wierońska, Joanna M.
Format: Article
Language:English
Subjects:
Acetylcholine receptors (muscarinic)
Activation
Amphetamines
Animal models
Animals
Antipsychotics
Biomedical and Life Sciences
Biomedicine
Brain
Brain slice preparation
Cortex (frontal)
Dizocilpine
Dopamine D2 receptors
Dopamine receptors
Excitatory postsynaptic potentials
Glutamatergic transmission
Glutamic acid receptors
Glutamic acid receptors (metabotropic)
Hyperactivity
Mental disorders
Neostriatum
Neurosciences
Original Investigation
Pattern recognition
Pharmacology/Toxicology
Positron emission tomography
Proteins
Psychiatry
Reversing
Rodents
Schizophrenia
Social interactions
Test procedures
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rationale Metabotropic glutamate receptors and muscarinic M 4 receptors have been proposed as novel targets for various brain disorders, including schizophrenia. Both receptors are coupled to G o/i proteins and are expressed in brain circuits that are important in schizophrenia. Therefore, their mutual activation may be an effective treatment and allow minimizing the doses of ligands required for optimal activity. Objectives In the present studies, subactive doses of mGlu 4 and M 4 activators (LSP4-2022 and VU152100, respectively) were administered to investigate the mutual interaction between mGlu 4 and M 4 receptors in animal models of schizophrenia. Methods The behavioral tests used were MK-801-induced hyperactivity, (±)-2.5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)-induced head twitches, the modified forced swim test, and MK-801-induced disruptions of social interactions and novel object recognition. DOI-induced spontaneous excitatory postsynaptic currents (sEPSCs) in brain slices and positron emission tomography (PET) in were used to establish the ability of these compounds to modulate the glutamatergic and dopaminergic systems. Rotarod was used to assess putative adverse effects. Results The mutual administration of subactive doses of LSP4-2022 and VU152100 exerted similar antipsychotic-like efficacy in animals as observed for active doses of both compounds, indicating their additive actions. VU152100 inhibited the DOI-induced frequency (but not amplitude) of sEPSCs in the frontal cortex, confirming presynaptic regulation of glutamate release. Both compounds reversed amphetamine-induced decrease in D 2 receptor levels in the striatum, as measured with [ 18 F]fallypride. The compounds did not induce any motor impartments when measured in rotarod test. Conclusions Based on our results, the simultaneous activation of M 4 and mGlu 4 receptors is beneficial in reversing MK-801- and amphetamine-induced schizophrenia-related changes in animals.
ISSN:0033-3158
1432-2072
DOI:10.1007/s00213-018-4980-y